{"schema_version":"secwatch.filing_event.v1","accession":"0001490978-23-000089","form_type":"8-K","ticker":"SDGR","cik":"0001490978","company_name":"Schrodinger, Inc.","filed_at":"2023-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.068491+00:00","generated_at":"2026-06-12T12:55:11.348968+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Schrödinger Q2 revenue $35.2M (-8.5% YoY); raises software revenue guidance, cuts drug discovery outlook","bullets":["Net income $4.3M vs net loss $47.7M YoY, driven by $45.0M other income and $20.4M tax benefit.","Non-GAAP net loss $56.8M vs $43.8M YoY; operating expenses rose 23.7% to $74.9M.","Software revenue growth guidance raised to 15%-18%; drug discovery revenue guidance cut to $50M-$70M from $70M-$90M.","IND cleared for CDC7 inhibitor SGR-2921; Phase 1 trial for AML/MDS expected in 2023.","Zai Lab elected not to continue discovery collaboration; program returned to wholly-owned by Schrödinger."],"urls":{"canonical":"https://secwatch.observer/filing/0001490978-23-000089","json":"https://secwatch.observer/filing/0001490978-23-000089.json","markdown":"https://secwatch.observer/filing/0001490978-23-000089.md","text":"https://secwatch.observer/filing/0001490978-23-000089.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1490978/000149097823000089/0001490978-23-000089-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1490978/000149097823000089/sdgr-20220802.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T12:55:11.348968+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c55c47aacb028db5977b58de9e28627b8a6ce755","claim":"Schrodinger, Inc. reported the quarter ended on June 30, 2023 results: revenue $35.2 million, net income $4.3 million. Guidance raised.","evidence_excerpt":"Quarter 2023 Financial Results Announces IND Clearance for CDC7 Inhibitor SGR-2921, Continued Progress for MALT1 Inhibitor SGR-1505 Delivers Second Quarter Total Revenue of $35.2 Million Raises 2023 Software Revenue Guidance and Reduces Drug Discovery Guidance New York, August 2, 2023 – Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1490978/000149097823000089/0001490978-23-000089-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended on June 30, 2023"},{"label":"Revenue","value":"$35.2 million"},{"label":"Net income","value":"$4.3 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}